New Cream Myregyna Aims to Bridge Female Libido Gap

A new product called Myregyna aims to address the low libido issues that affect many midlife women, potentially closing what has been referred to as the “orgasm gap.” Developed by Dr Iona Weir, a cellular biologist from New Zealand, the cream completed its clinical trials in May and is now available for purchase online. This innovative treatment could provide relief for a condition that impacts over one in three women at some point in their lives, often exacerbated by hormonal changes and other physical factors.

Dr Weir’s personal experience began in 2008 when a birth-repair surgery unexpectedly triggered a surgical menopause, sending her hormones into decline. She was informed by her gynaecologist about the potential consequences, particularly regarding libido and sexual pleasure. As a pioneer in the field of cellular apoptosis, she shifted her research focus to the creation of a plant-based cream that could help address vaginal atrophy, which significantly contributes to decreased sexual desire.

In her lab, Dr Weir developed Myregyna to be applied externally to the vulva and vagina. She believes that it can reverse some of the negative physical changes associated with menopause, such as dryness and decreased nerve sensitivity. “When a couple wants to have sex, it’s like sleeping on a mattress with no padding. It’s physically uncomfortable – even painful,” she explained.

The impact of low libido on women is profound, often leading to emotional distress and relationship challenges. Many women report a significant drop in their sexual desire, particularly as they age. Dr Weir’s pilot study revealed that numerous women had not engaged in sexual activity for years due to discomfort, with some expressing feelings of shame and isolation.

Changing Perspectives on Female Sexuality

As societal norms evolve, discussions about female sexuality are becoming more commonplace. The average life expectancy in the UK is approximately 81 years, which means many women could spend decades without intimacy if sexual issues go unaddressed. Increasingly, women are seeking solutions, viewing sexual pleasure as essential rather than optional.

According to Dr Grace Hatton, a women’s health specialist at Numan, about three in ten women seeking help for low libido inquire about testosterone supplements. Sales data from Lovehoney indicates that interest in products designed to enhance female sexual experience is on the rise, with a 10% increase in sales of orgasm-related items compared to the previous year.

Media portrayals of women’s sexuality are also shifting. From sex-positive podcasts to Netflix series like The Principles of Pleasure, cultural discussions are encouraging openness about female desire. Dr Weir asserts that there is currently no product that effectively addresses the physical aspects of female sexual dysfunction, highlighting the potential market for solutions like Myregyna.

The Medical Landscape for Women’s Libido Issues

The current landscape for treating female sexual dysfunction has seen attempts at pharmacological solutions, including Addyi and Vyleesi. Addyi was approved by the US Food and Drug Administration (FDA) in 2015, while Vyleesi was introduced in 2019. Both drugs have garnered mixed reviews, with efficacy questioned and side effects reported.

Investment analysts suggest that a successful female libido product could generate substantial revenue, potentially rivaling male-focused medications like Viagra, which peaked at annual sales of $2.1 billion in 2012. Yet, the market for female sexual health products remains limited compared to male counterparts, with experts like Derren Nathan from Hargreaves Lansdown noting that the current focus on midlife women may restrict broader appeal.

Dr Weir hopes to expand Myregyna’s reach globally, aiming for affordability and accessibility. “To find a manufacturing partner who shares our values, and make it available to women everywhere, ideally low cost on prescription,” she stated.

The quest for understanding female sexuality continues, with researchers acknowledging the complex interplay of biological, psychological, and social factors influencing sexual desire. As Dr Lori Brotto, a professor at the University of British Columbia, noted, effective treatment options need to consider these multifaceted dimensions.

Ultimately, Myregyna represents a promising step in addressing the unmet needs of women experiencing low libido, potentially enhancing their quality of life beyond the bedroom. As societal attitudes shift and scientific research progresses, more women may find the support they need to reclaim their sexual health and well-being.